Skip to content

Cytek Biosciences, Inc. CTKB Balance Sheet Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$31.81M+9.7%$28.98M-68.9%$93.28M+23.6%$75.47M-20.8%$95.3M-3.5%
$51.9M-17.0%$62.51M+10.4%$56.63M+0.7%$56.23M+2.2%$55.03M-9.2%
$49.79M+2.8%$48.43M-6.2%$51.65M+4.4%$49.49M+9.1%$45.35M+3.3%
$379.3M-3.2%$392M+0.9%$388.49M+1.5%$382.83M+0.6%$380.5M-4.0%
$20.47M+13.7%$18.01M-0.2%$18.05M-1.7%$18.35M+2.9%$17.83M-0.7%
$16.69M0.0%$16.7M0.0%$16.7M-0.1%$16.71M+0.2%$16.68M+0.1%
$15.7M-6.6%$16.82M-4.8%$17.68M-5.0%$18.6M-4.3%$19.43M-3.5%
$449.11M-2.7%$461.54M-6.7%$494.92M+0.3%$493.32M+2.2%$482.6M-3.4%
$6.74M+5.2%$6.41M-16.0%$7.63M+11.4%$6.85M+9.7%$6.25M+13.0%
$30.03M+5.4%$28.5M+74.7%$16.32M-1.9%$16.63M+5.8%$15.72M-2.4%
$80.94M+4.0%$77.8M+3.5%$75.21M+2.6%$73.27M+8.2%$67.69M0.0%
$386K-26.5%$525K-19.8%$655K-17.2%$791K-13.8%$918K-12.6%
$121.47M+1.4%$119.8M+3.0%$116.35M+0.5%$115.76M+12.4%$102.97M-0.8%
1B0.0%1B+781,150%128K+0.8%127K-0.8%128K-0.8%
-$120.6M-18.5%-$101.74M-76.4%-$57.66M-10.5%-$52.18M-12.0%-$46.6M-32.4%
$327.64M-4.1%$341.74M-9.7%$378.57M+0.3%$377.56M-0.5%$379.62M-4.1%
$449.11M-2.7%$461.54M-6.7%$494.92M+0.3%$493.32M+2.2%$482.6M-3.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Cytek Biosciences, Inc.'s total assets?
Cytek Biosciences, Inc. (CTKB) holds $449.1M in total assets, down 6.9% year over year.
How much debt does Cytek Biosciences, Inc. have?
Cytek Biosciences, Inc. carries $16.8M in total debt against $327.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
How much cash does Cytek Biosciences, Inc. have?
Cytek Biosciences, Inc. holds $31.8M in cash and equivalents.
Can Cytek Biosciences, Inc. cover its short-term obligations?
Its current ratio is 4.69 — current assets exceed current liabilities.
Where does Cytek Biosciences, Inc.'s balance sheet data come from?
Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.